A Swiss biotech success story award has been attributed to Novimmune at the recent Swiss Biotech days held in Basel.
GENEVA, SWITZERLAND/ SEPTEMBER 13, 2021 /
This award recognizes the collective efforts and dedication of past and present Novimmune colleagues that enabled the discovery, preclinical and clinical development of Emapalumab and its approval by the FDA in 2018.
Emapalumab is the first approved drug for the treatment of primary HLH (Hemophagocytic Lymphohistiocytosis), a severe and often lethal autoimmune condition affecting young children.
The Novimmune story continues under the brand Light Chain Bioscience and the progression of a bispecific and multispecific antibody pipeline.
